SCHEMBL3525259

SCHEMBL3525259

COC(=O)CCCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1ccc(N2CCOCC2)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR9 P51686 3/20 0.51
ALDH1A1 P00352 3/20 0.49
HPGD P15428 1/20 0.46
GAA P10253 2/20 0.43
KDM4E B2RXH2 1/20 0.43
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
PIK3CA P42336 3/20 0.41
MLNR O43193 1/20 0.41
BRD4 O60885 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PIK3CD O00329 3/20 0.39
PIK3CB P42338 2/20 0.39
PIK3CG P48736 2/20 0.39
MTOR P42345 1/20 0.38
CNR2 P34972 1/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3528240 0.85 ALDH1A1 (0.46) ALDH1A1HPGDGAAKMT2AMEN1
SCHEMBL3522927 0.79 KDM4E (0.50) ALDH1A1HPGDKDM4EKMT2AHSD17B10
SCHEMBL3525068 0.78 LMNA (0.51) CCR9ALDH1A1HPGDGAAKMT2A
SCHEMBL3528604 0.78 PTGES2 (0.47) ALDH1A1HPGDKMT2AHTT
SCHEMBL3527145 0.77 CCR2 (0.45) CCR9ALDH1A1GAAKMT2AMEN1
SCHEMBL3523802 0.77 LMNA (0.47) CCR9ALDH1A1HPGDKDM4EMAPT
SCHEMBL3523112 0.77 CCR9 (0.42) CCR9KMT2AMAPTLMNAHTT
SCHEMBL3523945 0.77 CCR2 (0.45) CCR9ALDH1A1GAAKDM4EKMT2A
SCHEMBL3522237 0.77 PKM (0.49) CCR9ALDH1A1HPGDKDM4EKMT2A
SCHEMBL3528825 0.76 ALDH1A1 (0.56) CCR9ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP CCR9 2577/4885ALDH1A1 1607/4885HPGD 497/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG CCR9 2408/4885ALDH1A1 1453/4885HPGD 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.